Novartis presented data showing its LCZ696 heart drug reduced cardiovascular deaths by 20% when compared with a rival treatment, suggesting the Swiss group has a multibillion-dollar product in the making.
from WSJ.com: What’s News US http://ift.tt/1B42leK
from Bobby Caples
from WordPress http://ift.tt/1qRjfde
from Bobby Caples
No comments:
Post a Comment